Authors
Daniel A Chamorro, María Fernanda Cadena Vizuete, Gina Layedra, Ramiro Isa-Jara, Marc A Giulianotti, Clemencia Pinilla, Maximiliano Pérez, Catalina D Alba Soto, Maria Laura Belaunzarán, Betiana Lerner, Guadalupe Gimenez
Published in
Sensors (Basel, Switzerland). Volume 26. Issue 20. Oct 14, 2026. Epub Oct 14, 2026.
Abstract
Chagas disease remains a major neglected tropical disease, highlighting the need for new anti-Trypanosoma cruzi compounds and improved approaches for their phenotypic evaluation. Here, we extended a previously developed Lab-on-a-Chip (LOC) platform integrating a serial dilution generator and automated label-free motility analysis (TR_KF) to the direct screening of extracellular T. cruzi trypomastigotes. The platform was validated in two steps using benznidazole as the reference drug. First, automated motility quantification in conventional 96-well plates was compared with manual Neubauer counting, yielding comparable concentration-response curves and IC50 values. Second, the complete LOC-TR_KF platform was compared with the conventional assay, producing an IC50 that was not significantly different from the reference method. The validated platform was subsequently applied to screen ten candidate samples, identifying combinatorial libraries 2161-X and 2160-X as the most active against trypomastigotes. Comparison with previously reported intracellular amastigote data revealed marked stage-dependent differences in compound activity, while pre-treatment with both libraries reduced parasite infectivity by approximately 50%. Overall, the integrated LOC-TR_KF platform provides pharmacological responses comparable to conventional assays while reducing assay-solution requirements, manual handling and enabling automated, label-free phenotypic screening of T. cruzi trypomastigotes.
PMID:
42944380
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0